Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a Shanghai-based clinical-stage RNA interference therapeutics company, has received Fast Track Designation from the U.S. Food and Drug Administration for BW-20805, its investigational small interfering RNA therapy targeting prekallikrein for the prevention of hereditary angioedema attacks. The designation comes as the company runs a global Phase II open-label study […]
Sentynl Therapeutics Inc., the United States-based rare disease subsidiary of Zydus Lifesciences Limited, has entered into a licensing agreement with South Korean biotechnology company PRG S&T to develop the investigational molecule Progerinin (SLC-D011) for Hutchinson-Gilford Progeria Syndrome, an ultra-rare genetic disorder that causes accelerated aging in children. The therapy has received orphan drug designation from […]
New PREDICT-DNA data suggests ultrasensitive ctDNA monitoring may outperform traditional markers in breast cancer relapse prediction. Read the full analysis.
Heru’s PretestPro completes four ophthalmic pretests in under two minutes on a VR wearable. Explore what this means for clinic workflow and clinical validation. Read more.
Baseimmune launches IPF pipeline using computational multi-pathway antigen design. Preclinical readouts due 2026-27. Discover what this means for fibrosis drug development.
